AbCellera Biologics Inc vs LTC Properties Inc — how do they compare? AbCellera Biologics Inc trades at $9.4 (market cap $2.99B), while LTC Properties Inc trades at $38.43 (market cap $2.05B). The key difference: AbCellera Biologics Inc is the larger of the two by market cap, and LTC Properties Inc pays a 5.98% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | LTC | |
|---|---|---|
Market Cap | $2.99B | $2.05B |
Sector | Health | Real Estate |
52-Week High | $9.76 | $42.81 |
52-Week Low | $2.78 | $33.98 |
Enterprise Value | $2.58B | $2.79B |
Dividend Yield | — | 5.98% |
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) surged 34.78% to $9.34, driven by positive Phase 2 trial results for its menopause drug ABCL635. Despite negative net income margins and cash burn, analyst consensus is strongly bullish with a $15.50 price target. The stock shows a bullish technical trend, with support at $8 and resistance at $10, though RSI levels indicate overbought conditions.
The outlook hinges on ABCL635's clinical progress and future revenue potential, but high valuation ratios and persistent losses pose significant risks. Investor sentiment is optimistic due to recent drug trial success, yet the company must demonstrate a path to profitability to justify current market enthusiasm.
LTC Properties (LTC) trades at $38.32, down 2.79% over 24 hours, with a bullish technical signal driven by moving averages. The REIT shows strong profitability with a 61.72% gross margin and 38.93% net margin, though recent earnings missed estimates in two of the last three quarters. Recent news highlights aggressive expansion in seniors housing acquisitions, including a $95 million SHOP purchase announced August 5, 2026.
Outlook is mixed: demographic trends support long-term demand, but execution risks from rapid growth and debt-funded investments pose challenges. Analysts are cautious with 59% hold ratings, reflecting concerns over earnings consistency amid high capital expenditures.
Trailing returns across standard periods
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →